Evaluation of the safety and efficacy in linagliptin with type 2 diabetic patients receiving hemodialysis therapy
Not Applicable
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000010099
- Lead Sponsor
- Saitama medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are inappropriate to use linagliptin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Episode of hypoglycemia at 12 weeks after the linagliptin treatment
- Secondary Outcome Measures
Name Time Method